ABBV AbbVie Inc.
Price Chart
Executive Summary
AbbVie reported Q1 2026 adjusted EPS of $2.65, above the prior company guidance range of $2.56-$2.60, and revenue of $15.002B (+12.4% YoY). The company raised full-year 2026 adjusted EPS guidance from $13.96-$14.16 to $14.08-$14.28, driven by strong growth in immunology (Skyrizi +30.9%, Rinvoq +23.3%) and neuroscience (+26.0%).
Key Financial Metrics
Actionable Insight
The beat on Q1 adjusted EPS and raised full-year guidance signal continued momentum in core therapeutic areas. Watch for FDA decisions on Skyrizi SC induction for Crohn's disease and Rinvoq for alopecia areata, which could further drive upside. Monitor Humira erosion trajectory and regulatory developments on trenibotulinumtoxinE.
Key Facts
- Q1 2026 net revenue $15.002B, +12.4% YoY reported, +10.3% operational
- Q1 2026 adjusted diluted EPS $2.65, +7.7% YoY; GAAP EPS $0.39, -45.8% YoY
- Full-year 2026 adjusted diluted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16
- Immunology revenue $7.290B (+16.4%), neuroscience $2.875B (+26.0%)
- Acquired IPR&D and milestones expense of $744M pre-tax ($0.41 per share drag)
Financial Impact
Revenue grew 12.4% to $15.002B, adjusted EPS up 7.7% to $2.65, full-year guidance raised by $0.12 at midpoint.
Risk Factors
- Humira revenue declining 38.6% YoY; Imbruvica down 24.7%
- FDA Complete Response Letter for trenibotulinumtoxinE (manufacturing issues)
- Reliance on Skyrizi and Rinvoq for growth; competition from biosimilars and new entrants
- Large non-cash charges (contingent consideration, amortization) depress GAAP earnings
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001551152-26-000013 |
| Document: abbv-20260429.htm | 0001551152-26-000013 |
| Document: 0001551152-26-000013-index-headers.html | 0001551152-26-000013 |
| Document: 0001551152-26-000013-index.html | 0001551152-26-000013 |
| Document: 0001551152-26-000013.txt | 0001551152-26-000013 |
| 8-K Data (Synthetic) | 0001551152-26-000013 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 31, 2026
9d ago
|
ANALYST-UPGRADE
| $221.54 $220.69 | ▼ −0.39% | ▲ +1.96% | $223.07 (+0.69%) |
|
May 21, 2026
19d ago
|
ANALYST-UPGRADE
| $205.12 $197.69 | ▼ −3.62% | ▼ −4.71% | $223.07 (+8.75%) |
|
May 18, 2026
23d ago
|
Court Ruling
| $209.41 $213.12 | ▲ +1.77% | ▲ +0.15% | $223.07 (+6.52%) |
|
May 1, 2026
5w ago
|
ANALYST-UPGRADE
| $221.54 $220.69 | ▼ −0.39% | ▲ +1.96% | $223.07 (+0.69%) |
|
Apr 29, 2026
5w ago
|
8-K
| $203.89 $206.11 | ▲ +1.09% | ▼ −2.02% | $223.07 (+9.41%) |
|
Apr 21, 2026
7w ago
|
ANALYST-UPGRADE
| $205.12 $197.69 | ▼ −3.62% | ▼ −4.71% | $223.07 (+8.75%) |
|
Apr 3, 2026
9w ago
|
8-K
| $204.99 $204.77 | ▼ −0.11% | ▼ −4.24% | $223.07 (+8.82%) |
|
Mar 23, 2026
11w ago
|
DEFA14A
| $203.51 $215.70 | ▲ +5.99% | ▲ +6.41% | $223.07 (+9.61%) |
|
Mar 2, 2026
14w ago
|
Insider Cluster
| $232.33 $225.58 | ▲ +2.91% | ▲ +1.70% | $223.07 (+3.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access